PROPTIMISE
The PROPTIMISE study is a psychosocial study embedded within the OPTIMISE (Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer) trial. OPTIMISE is a basket trial of precision guided molecularly targeted agents (PGT) in children and adolescents with advanced brain and solid tumours.
The PROPTIMISE study aims to explore the association between symptoms reported by patients/caregivers and Adverse Events (AEs) reported by clinicians, as well as assess the impact of trial participation on symptoms and trajectory of symptom burden.
Participants include patients aged 2 to 18 years who are enrolled in OPTIMISE (or proxy). OPTIMISE is being conducted at 3 sites in Canada as well as Australia-wide.
The PROPTIMISE study aims to explore the association between symptoms reported by patients/caregivers and Adverse Events (AEs) reported by clinicians, as well as assess the impact of trial participation on symptoms and trajectory of symptom burden.
Participants include patients aged 2 to 18 years who are enrolled in OPTIMISE (or proxy). OPTIMISE is being conducted at 3 sites in Canada as well as Australia-wide.